Larvol Delta - Cadrenal-Therapeutics-LateBreaking-Phase-2-Data-Demonstrate-Greater-Than-25-Reduction-in-Thrombotic-Events-in-HIT-for-FirstinClass-12LOX-Inhibitor-CAD1005-at-ISTH-2026-Congress

CAD-1005 - Cadrenal Therapeutics

https://www.globenewswire.com/news-release/2026/07/13/3326228/0/en/Cadrenal-Therapeutics-Late-Breaking-Phase-2-Data-Demonstrate-Greater-Than-25-Reduction-in-Thrombotic-Events-in-HIT-for-First-in-Class-12-LOX-Inhibitor-CAD-1005-at-ISTH-2026-Congres.html

Jul 13, 2026

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next